Pheton (NASDAQ:PTHL) vs. Electromed (NYSE:ELMD) Head-To-Head Review

Electromed (NYSE:ELMD) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Insider and Institutional Ownership

40.8% of Electromed shares are held by institutional investors. 14.0% of Electromed shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Electromed and Pheton, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Electromed	0	0	0	1	4.00
Pheton	0	0	0	0	0.00

Electromed currently has a consensus target price of $38.00, indicating a potential upside of 83.22%. Given Electromed’s stronger consensus rating and higher possible upside, equities analysts plainly believe Electromed is more favorable than Pheton.

Profitability

This table compares Electromed and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Electromed	11.34%	15.71%	13.37%
Pheton	N/A	N/A	N/A

Valuation and Earnings

This table compares Electromed and Pheton”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Electromed	$61.44 million	2.83	$5.15 million	$0.79	26.25
Pheton	$450,000.00	264.66	-$660,000.00	N/A	N/A

Electromed has higher revenue and earnings than Pheton.

Summary

Electromed beats Pheton on 10 of the 11 factors compared between the two stocks.

About Electromed

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.